Month: November 2020

After many years of good management of their high blood pressure, Americans are letting that control slip: the number of Americans with uncontrolled blood pressure rates has been rising. And while this trend has been creeping up since 2015, Covid-19, as with most things today, seems to have left its mark.   These increasing numbers aren’t
0 Comments
A new research study detects pre-existing antibody-driven immunity against SARS-CoV-2 in some individuals, with higher rates in uninfected children. Different age groups appear to have different responses to COVID-19, with kids often presenting with mild or no symptoms. However, the reason for this remains relatively unclear.  Although COVID-19 is at the forefront of the news
0 Comments
KENILWORTH, N.J.–(BUSINESS WIRE) November 16, 2020 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP)1
0 Comments
FDA Approves Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy (lonafarnib) for the
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 20 2020 Today, the U.S. Food and Drug Administration approved Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older. Zokinvy is not approved for use in patients with
0 Comments
Omalizumab (Xolair) maintained efficacy for chronic rhinosinusitis with nasal polyps, a researcher reported. In an open-label extension study of two, 24-week clinical trials, omalizumab was associated with significant improvements in nasal polyp scores (mean change -0.97, 95% CI -1.25 to -0.69), nasal congestion scores (mean change -0.99, 95% CI -1.14 to -0.83), and Sino-Nasal Outcome
0 Comments
Combination treatment with the investigational, selective KIT inhibitor PLX9486 plus sunitinib (Sutent) was safe and active in patients with relapsed or refractory gastrointestinal stromal tumors (GIST), a small phase I/II study found. Among 18 patients treated with the combination, one achieved a complete response, two had partial responses, and another had an unconfirmed partial response,
0 Comments
The full 5-year results of a long-term extension study of tildrakizumab for psoriasis show a high rate of sustained disease control coupled with a favorable safety profile during more than 5,400 patient-years of prospective follow-up, Diamont Thaçi, MD, PhD, reported at the virtual annual congress of the European Academy of Dermatology and Venereology. For example, 89% of
0 Comments
Many of us are frittering away time on Facebook or Twitter as we hunker down at home during the pandemic. But there’s a potential upside to all this social media engagement: It lets public health officials know how people feel about Covid-19 restrictions and can be used to encourage compliance. Australian researchers found that social
0 Comments
A novel algorithm-based disease management program, led by pharmacists and nonlicensed navigators, optimized cholesterol and blood pressure levels in high-risk patients, according to an interim report from the first 5000 patients. Mean low-density lipoprotein cholesterol (LDL-C) levels fell from 125 mg/dL to 73 mg/dL among those who finished active treatment titration and from 133 mg/dL
0 Comments
‘Manifesting’ has become a real buzz word – and it’s one our columnist Grace Victory uses daily. Here, she shares everything you need to know about the power of ‘manifestation’ When I was 23, I began searching for ways to connect to myself moredeeply, as well as how to create a life that I really
0 Comments
View of Corporate and Research and Development Headquarters of Regeneron Pharmaceuticals on Old Saw Mill River Road in Tarrytown, New York. Lev Radin | LightRocket | Getty Images The Food and Drug Administration on Saturday granted an emergency use authorization for Regeneron‘s Covid-19 antibody treatment, the experimental therapy given to President Donald Trump when he
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 20 2020 The results gained in a study involving approximately one million Danish children increase the understanding of how socio-economic differences in childhood affect the development of mental disorders in the Nordic countries. Researchers at the University of Helsinki, Aarhus University and the University of Manchester have investigated the link
0 Comments
Owning a dog while pregnant appeared to shape children’s immune systems well into adolescence, a researcher reported. In a cohort of 1,193 mother-child pairs in southeast Michigan, the area under the curve for immunoglobulin E levels over ages 10-14 (“IgE trajectory”) was 28.8% lower in children with prenatal pet exposure vs children whose mothers kept
0 Comments
Treatment with an investigational albumin-bound mTOR inhibitor showed long-lasting responses in patients with advanced malignant perivascular epithelioid cell tumors (PEComa), extended follow-up from the single-arm AMPECT study showed. On independent review, the overall response rate (ORR) with nab-sirolimus in 31 malignant PEComa patients was 39% (95% CI 22-58), including one complete response, meeting the primary
0 Comments
The interventional cardiology community is mourning the loss of Prof Anthony “Tony” Gershlick, MBBS, who died November 20 of COVID-19. He was 69. Gershlick was a “talented, dedicated and much loved colleague,” reads a statement issued by the University of Leicester, where he was affiliated for more than three decades. Gershlick, a consultant cardiologist at
0 Comments
To assist in the search for potential drugs, an international team led by Harvard Medical School researchers has developed software capable of preparing and screening billions of chemical compounds. Such programs were previously limited to sifting through about 1 million to 10 million compounds each. Read more: https://hms.harvard.edu/news/galaxy-drug-candidates UPDATE, MARCH 18 Amid the COVID-19 global
0 Comments
This content originally appeared on TCOYD: Taking Control of Your Diabetes. Republished with permission. By Sarah Severance This is a fun twist on a traditional mimosa, but keep in mind it does have about 22 grams of carb and 10 grams of sugar per serving. To keep the carbs and sugar lower, you can make
0 Comments
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Scientists involved in oversight of the Operation Warp Speed COVID-19 vaccine trials are tempering excitement about efficacy, noting that the studies haven’t shown yet whether the products can prevent transmission of the SARS-CoV-2 virus. “We don’t know if people can become
0 Comments
Because of the stalled economy, especially reductions in air and auto traffic, US greenhouse gas emissions are expected to drop 9.2% in 2020, their lowest level in three decades, according to a study by BloombergNEF. Earlier studies have shown reductions in particulate matter, both here and abroad. That remarkable 9.2% drop is partially offset by
0 Comments
The Dean of Brown University’s School of Public Health, Dr. Ashish Jha, warned that the United States could “see another 100,000 deaths by Inauguration Day” as the coronavirus death rate climbs and public health professionals raise the alarm.  “Once we get into the spring we easily could be at 450,000 or even 500,000 deaths,” Jha
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 16, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 20 2020 In a new publication from Cardiovascular Innovations and Applications, Lei Zhang, Tiewei Lv, Xiaoyan Liu, Chuan Feng, Min Zheng, Jie Tian and Huichao Sun from the Children’s Hospital of Chongqing Medical University, Chongqing, China and the Chongqing Key Laboratory of Pediatrics, Chongqing, China consider a case of pediatric
0 Comments